Aspen Australia have signed a license agreement with Actavis, taking on the sales, marketing and distribution of two products, Neotigason and Rapilysin.
Aspen Australia have signed a license agreement with Actavis, taking on the sales, marketing and distribution of two products, Neotigason and Rapilysin. The former is for the treatment of psoriasis and the latter for acute myocardial infarction (heart attack). Both are major, niche products in their respective therapeutic areas with combined sales of around $6 million. The effective starting date of this agreement is 31 March.
We are very fortunate that a company like Actavis, which is one of the world’s leading players in the development, manufacture, and sale of first-class generic pharmaceuticals, would choose Aspen Australia to partner them in this country. This shows the confidence that major companies now have in Aspen’s ability to take on old brands and revive or grow them. Our track record speaks for itself.
With the addition of these new products to our portfolio, Aspen Australia is now sitting on annualised sales of over $135 million – and growing.
Content Last Reviewed On July 16, 2018